Imatinib carbaldehyde is primarily used in the development of targeted cancer therapies. It serves as a key intermediate in the synthesis of more complex molecules designed to inhibit specific tyrosine kinases, which are often overactive in certain types of cancer. This compound is particularly valuable in the creation of prodrugs or modified versions of imatinib, enhancing its delivery, efficacy, or specificity. Researchers also utilize it in the study of drug resistance mechanisms, as it helps in understanding how cancer cells evade treatment. Additionally, it plays a role in the design of novel therapeutic agents for diseases like chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs), where tyrosine kinase inhibition is crucial.